A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: Results from NOOC1 from the North Central Cancer Treatment Group

Cancer

Volumn 110, Issue 6, 2007, Pages 1396-1403

  Jatoi, Aminah ^a   Dakhil, Shaker R ^b   Nguyen, Phuong L ^a   Sloan, Jeff A ^a   Kugler, John W ^c   Rowland Jr , Kendrith M ^d   Soori, Gamini S ^e   Wender, Donald B ^f   Fitch, Tom R ^g   Novotny, Paul J ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c Illinois Oncol Res Assoc CCOP   (United States)

^d Carle Cancer Center CCOP   (United States)

^e Missouri Valley Cancer Consortium ^*  (United States)

^f Siouxland Hematology Oncology Associates   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Anorexia weight loss syndrome; Cancer; Etanercept; Survival; Tumor necrosis factor

Indexed keywords

ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPOTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; ANTINEOPLASTIC AGENTS; APPETITE; BIOLOGICAL RESPONSE MODIFIERS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN; WEIGHT LOSS;

EID: 34548732637     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22944     Document Type: Article

References (17)

1. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69:491-497.
2. Chamberlain JS. Cachexia in cancer-zeroing in on myosin. N Engl J Med. 2004;351:2124-2125.
3. Llovera M, Garcia-Martinez C, Lopez-Soariano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998;142:183-189.
4. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289:2363-2366.
5. Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumor-bearing rates is associated with MyoD down-regulation. Int J Oncol. 2005;26:1663-1668.
6. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol. 1999;277:R850-R855.
7. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-2179.
8. Sloan JA, Loprinzi CL, Laurie JA, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001;19:3539-3546.
9. Jatoi A, Egner J, Loprinzi CL, et al. Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer. 2004;12:640-644.
10. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137-1146.
11. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662-3673.
12. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
13. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567-573.
14. Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care. 2004;7:427-734.
15. Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12:3099-3108.
16. Pastor IJ, Laso FJ, Romero A, et al. -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res. 2005;29:1928-1931.
17. Achrol AS, Pawlikowska L, McCulloch CE, et al. Tumor necrosis factor-alpha-238 G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke. 2006;37:231-234.